Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Calliditas Expects EMA's CHMP Opinion For Nefecon In Q2

  • Calliditas Therapeutics AB (NASDAQ:CALT) says that the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) can be expected in Q2 of 2022.
  • In its review of the marketing authorization application (MAA) for Nefecon, the CHMP has informed us that they will issue an additional list of questions related to manufacturing-related information, resulting in EMA's opinion slipping into Q2. 
  • The continued review does not relate to the safety or efficacy of Nefecon, and there are no plans for an oral explanation.
  • Related: Calliditas Shares Rally After FDA's Accelerated Approval For Budesonide For Kidney Disease.
  • "Targeting an opinion in Q1 was ambitious in light of the fact that this is the first time the EMA has reviewed a drug for this indication," said CEO Renée Aguiar-Lucander. 
  • Price Action: CALT shares are down 5.44% at $17.90 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.